Endomag
We're creating the next generation of instruments to help surgeons and radiologists tackle breast cancer. #Sentimag #Magseed #Sienna.
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 57 % | 19 % | 63 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (22 %) | (24 %) | (22 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (16 %) | (20 %) | (22 %) | (1 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Endomag is a pioneering company in the medical technology sector, specializing in advanced solutions for breast cancer care. The company serves healthcare providers, particularly breast cancer surgeons and radiologists, by offering a unique platform that combines lesion localization and sentinel node biopsy. This platform eliminates the need for wires and radioactive materials, thereby enhancing the precision and flexibility of breast cancer surgeries. Operating in the global healthcare market, Endomag's business model revolves around the sale and distribution of its proprietary medical devices and technologies. Revenue is generated through direct sales to hospitals and clinics, as well as through partnerships with medical institutions. Endomag's innovative approach aims to improve surgical outcomes and patient experiences, making it a key player in the fight against breast cancer.
Keywords: breast cancer, lesion localization, sentinel node biopsy, medical technology, healthcare, surgery, precision, flexibility, non-radioactive, innovation.